RMC No. 101-2020: Addendum to VAT-Exempt Drugs for Hypertension, Diabetes and High Cholesterol

RMC No. 101-2020 publishes the FDA addendum to VAT-exempt drugs for hypertension, diabetes, and high cholesterol under RA 11467. Businesses selling, purchasing, prescribing, distributing, or accounting for medicines for hypertension, diabetes, and high cholesterol must immediately check whether their drug databases, point-of-sale systems, invoices, tax coding, and VAT treatment reflect the expanded list of VAT-exempt […]

RMC No. 2-2019: VAT Exemption on Diabetes, High-Cholesterol and Hypertension Drugs in the Philippines

RMC No. 2-2019 implements VAT exemption for FDA-listed diabetes, high-cholesterol, and hypertension drugs, with EDPMS and price reporting rules. Drug manufacturers, distributors, wholesalers, retailers, hospital pharmacies, and other FDA-licensed establishments must apply VAT exemption only to qualified diabetes, high-cholesterol, and hypertension medicines in final form, and only when those medicines are included in the FDA-published […]